N@N

Colin Bristow Maintained (VRTX) at Strong Buy with Increased Target to $375 on, Feb 8th, 2023

Colin Bristow of UBS, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $373 to $375 on, Feb 8th, 2023.

Colin has made no other calls on VRTX in the last 4 months.

There are 10 other peers that have a rating on VRTX. Out of the 10 peers that are also analyzing VRTX, 4 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $303 on, Tuesday, February 7th, 2023
• Michael Yee of "Jefferies" Downgraded from Strong Buy to Hold and Held Target at $340 on, Monday, December 19th, 2022
• Brian Skorney of "Baird" Maintained at Hold and Held Target at $280 on, Monday, October 31st, 2022
• Paul Matteis of "Stifel" Maintained at Hold and Held Target at $289 on, Sunday, October 30th, 2022

These are the ratings of the 6 analyists that currently disagree with Colin

---

• Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $340 on, Thursday, November 17th, 2022
• Hartaj Singh of "Oppenheimer" Maintained at Buy and Held Target at $350 on, Friday, November 11th, 2022
• Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $442 on, Monday, October 31st, 2022
• Phil Nadeau of "TD Cowen" Maintained at Buy with Increased Target to $330 on, Friday, October 28th, 2022
• Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $335 on, Friday, October 28th, 2022
• Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $327 on, Monday, October 24th, 2022

Contributing Sources

---